Emerging trends of phytochemicals as ferroptosis modulators in cancer therapy - 22/03/24
Abstract |
Ferroptosis, a novel form of regulated cell death characterized by dependence on iron and lipid peroxidation, has been implicated in a wide range of clinical conditions including neurological diseases, cardiovascular disorders, acute kidney failure, and various types of cancer. Therefore, it is critical to suppress cancer progression and proliferation. Ferroptosis can be triggered in cancer cells and some normal cells by synthetic substances, such as erastin, Ras-selective lethal small molecule-3, or clinical pharmaceuticals. Natural bioactive compounds are traditional drug discovery tools, and some have been therapeutically used as dietary additives or pharmaceutical agents against various malignancies. The fact that natural products have multiple targets and minimal side effects has led to notable advances in anticancer research. Research has indicated that ferroptosis can also be induced by natural compounds during cancer treatment. In this review, we focused on the most recent developments in emerging molecular processes and the significance of ferroptosis in cancer. To provide new perspectives on the future development of ferroptosis-related anticancer medications, we also provide a summary of the implications of natural phytochemicals in triggering ferroptosis through ROS production and ferritinophagy induction in a variety of malignancies.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Ferroptosis regulates cancer cell death in various carcinomas. |
• | Targeting ferroptosis for cancer therapeutics could be an attractive approach. |
• | Natural compounds induce ferroptosis in different cancer. |
• | Alkaloids, terpenes, phenols, flavonoids, saponin induces ferroptosis. |
Abbreviations : ACC, ACSL3, ACSL4, AML, ARE, BC, BCL2, CHAC1, CoQ10, CRC, CUL3, Cys, DMT1, ER, FDA, FDFT1, Fer-1, FSP1, FT, FTH1, FTL, GC, GPX4, GR, GSH, GSK3b, GSS, GSSG, HCCs, HMOX-1, HO-1, Keap1, LDH, LIP, Lip-1, LPS, MDA, MUFA, NADPH, NCOA4, NF-kB, NRF2, NSCLC, PE, PLs, PUFA, PUFA-CoA, PUFA-PL, PUFA-PLOOH, ROS, SLC1A4, SLC40A1, STEAP3, TF, TfR1, TNBC, TXNRD1, Ub
Keywords : Ferroptosis, Natural products, Cancer therapy, Apoptosis, Signaling pathway
Plan
Vol 173
Article 116363- avril 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?